The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER+ Breast Cancer Cells by Repressing ERα-Mediated Expression of the Migratory Factor TFF1
- PMID: 30655324
- DOI: 10.1158/1541-7786.MCR-18-1039
The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER+ Breast Cancer Cells by Repressing ERα-Mediated Expression of the Migratory Factor TFF1
Abstract
Core binding factor β (CBFβ), the essential coregulator of RUNX transcription factors, is one of the most frequently mutated genes in estrogen receptor-positive (ER+) breast cancer. Many of these mutations are nonsense mutations and are predicted to result in loss of function, suggesting a tumor suppressor role for CBFβ. However, the impact of missense mutations and the loss of CBFβ in ER+ breast cancer cells have not been determined. Here we demonstrate that missense mutations in CBFβ accumulate near the Runt domain-binding region. These mutations inhibit the ability of CBFβ to form CBFβ-Runx-DNA complexes. We further show that deletion of CBFβ, using CRISPR-Cas9, in ER+ MCF7 cells results in an increase in cell migration. This increase in migration is dependent on the presence of ERα. Analysis of the potential mechanism revealed that the increase in migration is driven by the coregulation of Trefoil factor 1 (TFF1) by CBFβ and ERα. RUNX1-CBFβ acts to repress ERα-activated expression of TFF1. TFF1 is a motogen that stimulates migration and we show that knockdown of TFF1 in CBFβ-/- cells inhibits the migratory phenotype. Our findings reveal a new mechanism by which RUNX1-CBFβ and ERα combine to regulate gene expression and a new role for RUNX1-CBFβ in the prevention of cell migration by suppressing the expression of the motogen TFF1. IMPLICATIONS: Mutations in CBFβ contribute to the development of breast cancer by inducing a metastatic phenotype that is dependent on ER.
©2019 American Association for Cancer Research.
Similar articles
-
The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context.Cells. 2023 Feb 16;12(4):641. doi: 10.3390/cells12040641. Cells. 2023. PMID: 36831308 Free PMC article. Review.
-
Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells.Mol Endocrinol. 2012 Jun;26(6):955-66. doi: 10.1210/me.2012-1066. Epub 2012 Apr 27. Mol Endocrinol. 2012. PMID: 22543272 Free PMC article.
-
Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.EBioMedicine. 2016 Jun;8:117-131. doi: 10.1016/j.ebiom.2016.04.032. Epub 2016 Apr 29. EBioMedicine. 2016. PMID: 27428424 Free PMC article.
-
The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells.Mol Cancer. 2010 Jun 30;9:171. doi: 10.1186/1476-4598-9-171. Mol Cancer. 2010. PMID: 20591170 Free PMC article.
-
Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.Cancer Treat Res. 2010;145:127-47. doi: 10.1007/978-0-387-69259-3_8. Cancer Treat Res. 2010. PMID: 20306249 Review.
Cited by
-
The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context.Cells. 2023 Feb 16;12(4):641. doi: 10.3390/cells12040641. Cells. 2023. PMID: 36831308 Free PMC article. Review.
-
Core binding factor subunit β plays diverse and essential roles in the male germline.Front Cell Dev Biol. 2023 Nov 2;11:1284184. doi: 10.3389/fcell.2023.1284184. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38020932 Free PMC article.
-
Cancer-Associated Exosomal CBFB Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of Breast Cancer Progression.Dis Markers. 2022 Jul 19;2022:8446629. doi: 10.1155/2022/8446629. eCollection 2022. Dis Markers. 2022. PMID: 35903297 Free PMC article.
-
The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.Hum Genomics. 2023 Jul 15;17(1):64. doi: 10.1186/s40246-023-00511-6. Hum Genomics. 2023. PMID: 37454130 Free PMC article.
-
RUNX1 Dosage in Development and Cancer.Mol Cells. 2020 Feb 29;43(2):126-138. doi: 10.14348/molcells.2019.0301. Mol Cells. 2020. PMID: 31991535 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous